ArticleJournal of medicinal chemistry2024
Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant
Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination.Cell reports. Medicine · 2026Article
- A novel penicillin-binding protein inhibitor with unprecedented intracellular activity eradicates multiple pathogenic bacteria.PLoS pathogens · 2026Article
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor ofAntimicrobial agents and chemotherapy · 2026Article
- Antibiotic hybrids: A promising strategy to replenish the pipeline and combat antimicrobial resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Article
- Computational Approaches and Structure-Based Drug Design of CAIs.Sub-cellular biochemistry · 2026Review
- Drug Design of Carbonic Anhydrase Inhibitors.Sub-cellular biochemistry · 2026Review
- Future Directions in Biotechnological and Pharmacological Applications of CAIs.Sub-cellular biochemistry · 2026Review
- Hybrid and Chimeric Heterocycles for the Inhibition of Carbonic Anhydrases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multi-faceted exploration of the novel active γ-carbonic anhydrase PaCAγ1 in the human pathogen Pseudomonas aeruginosa.International journal of biological macromolecules · 2025Article
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.European journal of medicinal chemistry · 2025Article
- A novel peptide mimetic, brilacidin, for combating multidrug-resistant Neisseria gonorrhoeae.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The development of antibacterial drugs with new mechanisms of action is crucial in combating the rise of antibiotic-resistant infections. Bacterial carbonic anhydrases (CAs, EC 4.2.1.1) have been validated as promising antibacterial targets against pathogens such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.